文 献Late breaking cohort studies 2015年4月，大阪10）Nicholls SJ, Kastelein JJ, Schwartz GG, Bash D, Rosenson RS, Cavender MA, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA 2014; 311: 252-62.11）Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-66.12）White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370: 1702-11.13）Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119-31.14）Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardio 2013; 61: 404-10.15）Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: A pilot study. Circulation 2015; 132: 1395-403. 16）Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357–61.661）植田真一郎，森本剛ら. 第79回日本循環器学会 2）Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation 2008; 118: 2702-9.3）Saito M, Fukami K, Hiramori K, Haze K, Sumiyoshi T, Kasagi H, et al. Long-term prognosis of patients with acute myocardial infarction: Is mortality and morbidity as low as the incidence of ischemic heart disease in Japan? Am Heart J 1987; 113: 891-7.4）Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.5）American Diabetes Association. 8. Cardiovascular disease and risk management. Diabetes Care 2016; 39(Suppl. 1): S60–S71.6）Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment PanelⅢGuidelines. Circulation 2004; 110: 227-39.7）Nakatani D, Sakata Y, Mizuno H, Shimizu M, Suna S, Usami M, et al. Impact of diabetes mellitus on rehospitalization for heart failure among survivors of acute myocardial infarction in the percutaneous coronary intervention era. Circ J 2009; 73: 662-6.8）Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 1685-95.9）Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE -/- mice. J Cardiovasc Pharmacol 2009; 53: 60-5.
元のページ ../index.html#80